RBC Capital on Neurocrine Bio. (NBIX): 'We See Room for Additional Share Upside'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $145.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
